Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma

Cancer Prevention Research

Volumn 6, Issue 12, 2013, Pages 1293-1303

  Song, Nu Ry ^a,c   Lee, Eunjung ^b   Byun, Sanguine ^a,b,c   Kim, Jong Eun ^a,b,d   Mottamal, Madhusoodanan ^a   Park, Jung Han Yoon ^e   Lim, Soon Sung ^e   Bode, Ann M ^a   Lee, Hyong Joo ^b,c   Lee, Ki Won ^b,c,d   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University   (South Korea)

^e Hallym University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN E; FLAVONOID; GLYCOGEN SYNTHASE KINASE 3BETA; ISOANGUSTONE A; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; FLOW CYTOMETRY; GLYCYRRHIZA; GLYCYRRHIZIC ACID; HUMANS; IMMUNOPRECIPITATION; ISOFLAVONES; MALE; MAP KINASE KINASE 4; MAP KINASE KINASE 7; MELANOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890522831     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0134     Document Type: Article

References (42)

1. Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci 2005;50:1807-12.
2. Fuhrman B, Volkova N, Kaplan M, Presser D, Attias J, Hayek T, et al. Antiatherosclerotic effects of licorice extract supplementation on hypercholesterolemic patients: increased resistance of LDL to atherogenic modifications, reduced plasma lipid levels, and decreased systolic blood pressure. Nutrition 2002;18:268-73.
3. Fukai T, Marumo A, Kaitou K, Kanda T, Terada S, Nomura T. Anti-Helicobacter pylori flavonoids from licorice extract. Life Sci 2002;71:1449-63.
4. Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer 2001;39:1-11.
5. Aydemir EA, Oz ES, Gokturk RS, Ozkan G, Fiskin K. Glycyrrhiza flavescens subsp. antalyensis exerts antiproliferative effects on melanoma cells via altering TNF-alpha and IFN-alpha levels. Food Chem Toxicol 2011;49:820-8.
6. Kobayashi M, Fujita K, Katakura T, Utsunomiya T, Pollard RB, Suzuki F. Inhibitory effect of glycyrrhizin on experimental pulmonary metastasis in mice inoculated with B16 melanoma. Anticancer Res 2002;22:4053-8.
7. Rossi T, Benassi L, Magnoni C, Ruberto AI, Coppi A, Baggio G. Effects of glycyrrhizin on UVB-irradiated melanoma cells. In Vivo 2005;19:319-22.
8. Shintani S, Murase H, Tsukagoshi H, Shiigai T. Glycyrrhizin (licorice)-induced hypokalemic myopathy. Report of 2 cases and review of the literature. Eur Neurol 1992;32:44-51.
9. Stormer FC, Reistad R, Alexander J. Glycyrrhizic acid in liquorice - evaluation of health hazard. Food Chem Toxicol 1993;31:303-12.
10. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
11. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
12. Sherr CJ. D-type cyclins. Trends Biochem Sci 1995;20:187-90.
13. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
14. Barbieri F, Lorenzi P, Ragni N, Schettini G, Bruzzo C, Pedulla F, et al. Overexpression of cyclin D1 is associated with poor survival in epithelial ovarian cancer. Oncology 2004;66:310-5.
15. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 2004;145:5439-47.
16. Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, et al. Correlation of beta-catenin and cyclin D1 expression in colon cancers. Oncology 2001;61:226-33.
17. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011;11:558-72.
18. Bastian BC, Kashani-Sabet M, Hamm H, Godfrey T, Moore DH II, Brocker EB, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000;60:1968-73.
19. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
20. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
21. Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr Oncol Rep 2012;14:129-38.
22. Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M, et al. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12:1139-65.
23. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510.
24. Liang J, Slingerland JM. Multiple roles of the PI3K/PKB(Akt) pathway in cell cycle progression. Cell Cycle 2003;2:339-45.
25. Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008;20:581-9.
26. Lee YS, Kim SH, Kim JK, Shin HK, Kang YH, Park JH, et al. Rapid identification and preparative isolation of antioxidant components in licorice. J Sep Sci 2010;33:664-71.
27. Lee E, Son JE, Byun S, Lee SJ, Kim YA, Liu K, et al. CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth. Toxicol Appl Pharmacol 2013;272:12-20.
28. Bernstein FC, Koetzle TF, Williams GJ, Meyer EF Jr, Brice MD, Rodgers JR, et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 1977;112:535-42.
29. Akimoto M, Kimura M, Sawano A, Iwasaki H, Nakajima Y, Matano S, et al. [Prevention of cancer chemotherapeutic agent-induced toxicity in postoperative breast cancer patients with glycyrrhizin (SNMC)]. Gan No Rinsho 1986;32:869-72.
30. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
31. Nomura T, Fukai T. Phenolic constituents of licorice (Glycyrrhiza species). Fortschr Chem Org Naturst 1998;73:1-158.
32. Yasukawa K, Takido M, Takeuchi M, Nakagawa S. [Inhibitory effect of glycyrrhizin and caffeine on two-stage carcinogenesis in mice]. Yakugaku Zasshi 1988;108:794-6.
33. Abe H, Ohya N, Yamamoto KF, Shibuya T, Arichi S, Odashima S. Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells. Eur J Cancer Clin Oncol 1987;23:1549-55.
34. Liu W, Kato M, Akhand AA, Hayakawa A, Takemura M, Yoshida S, et al. The herbal medicine sho-saiko-to inhibits the growth of malignant melanoma cells by upregulating Fas-mediated apoptosis and arresting cell cycle through downregulation of cyclin dependent kinases. Int J Oncol 1998;12:1321-6.
35. Johns C. Glycyrrhizic acid toxicity caused by consumption of licorice candy cigars. CJEM 2009;11:94-6.
36. Nguyen-Ba G, Vasseur P. Epigenetic events during the process of cell transformation induced by carcinogens (review). Oncol Rep 1999;6:925-32.
37. 1 cyclins. Curr Opin Cell Biol 1994;6:842-6.
38. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J 2012;18:142-7.
39. Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 2011;24:902-21.
40. Raymond E, Hammel P, Dreyer C, Maatescu C, Hentic O, Ruszniewski P, et al. Sunitinib in pancreatic neuroendocrine tumors. Target Oncol 2012;7:117-25.
41. Sciarra A, Gentile V, Salciccia S, Alfarone A, Di Silverio F. New antiangiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. Rev Recent Clin Trials 2008;3:97-103.
42. Petrelli A, Valabrega G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother 2009;10:589-600.